Early administered antibiotics do not impact mortality in critically ill patients with COVID-19.
COVID-19 may mimic bacterial pneumonia and, therefore, antibiotics for possible bacterial coinfection were frequently administered. We conducted a retrospective analysis aimed at describing the impact of early antibiotic therapy (i.e., before intensive care unit [ICU] admission) on mortality and delayed severe healthcare-associated infections in the ICU.
However, our preliminary results illustrate that early administered antibiotics do not appear to significantly impact mortality or delayed hospital-acquired infections in critically ill patients and call into question the utility of early treatment of a presumptive bacterial superinfection in COVID-19 patients. Large multi-centric studies are urgently needed to investigate the impact of early antibiotics therapy on mortality, subsequent healthcare associated infections and ICU complications (i.e., duration of mechanical ventilation).
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.